Popular Trials
Behavioural Intervention
Lee Silverman Voice Treatment for Parkinson's Disease
The purpose of this study is to evaluate the impact of a non-invasive brain stimulation technique called transcranial magnetic stimulation (TMS) on voice/speech treatment in people with Parkinson's Disease (PD), through the use of speech and voice analysis, examination of voice box, and brain imaging methods.
Norepinephrine Precursor
Droxidopa for Freezing of Gait
Since droxidopa has been approved in Japan for treating freezing of gait in Parkinson's disease patients, this is to confirm and further investigate the safety and efficacy using a similar dose. The possible beneficial effects on cognition in mildly cognitively impaired Parkinson's disease patients will also be tested, since this problem in Parkinson's disease may be associated with decreased brain synthesis of norepinephrine (a neurotransmitter associated with multiple brain functions). During this 11 week study, droxidopa will be slowly titrated up to 600 mg daily. Walking and freezing of gait will be evaluated and rated. Cognitive functions will be evaluated by a computer-based program.
Behavioural Intervention
CranioSacral Therapy for Parkinson's Disease
This trial is studying the effect of CranioSacral Integrative therapy on Parkinson's Diseased Patients. This therapy is given biweekly for 3 months, and the investigators expect to see a positive change in the symptoms of the patients.
Popular Filters
Trials for Parkinson's Disease Patients
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Nicotinic Acetylcholine Receptor Agonist
Nicotine patch +1 More for Parkinson's Disease
This trial uses nicotine patches to help people with Parkinson's Disease who have impulse control issues. The nicotine in the patches mimics a brain chemical that helps manage behavior. The goal is to see if this can control impulsive behaviors without reducing Parkinson's medications. Nicotine has been studied for its potential benefits in Parkinson's disease, including symptom improvement and reduction of levodopa-induced dyskinesias.
Monoamine Oxidase Inhibitor
Rasagiline for Parkinson's Disease
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
Trials for PD Patients
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Nicotinic Acetylcholine Receptor Agonist
Nicotine patch +1 More for Parkinson's Disease
This trial uses nicotine patches to help people with Parkinson's Disease who have impulse control issues. The nicotine in the patches mimics a brain chemical that helps manage behavior. The goal is to see if this can control impulsive behaviors without reducing Parkinson's medications. Nicotine has been studied for its potential benefits in Parkinson's disease, including symptom improvement and reduction of levodopa-induced dyskinesias.
Monoamine Oxidase Inhibitor
Rasagiline for Parkinson's Disease
A decrease or loss of the sense of smell is very common in patients with Parkinson's Disease even in the earliest stages of the disease. There have been no treatments that have been proven to improve sense of smell in patients with Parkinson's Disease. Rasagiline (brand name: Azilect) was approved by the U.S. Food and Drug Administration (FDA) on May 16th 2006 to be used by Parkinson's patients to treat the motor symptoms associated with the disease. The purpose of this study is to see if there is change in sense of smell after starting Rasagiline.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
Phase 3 Trials
Dopamine Agonist
Accordion Pillâ„¢ Carbidopa/Levodopa for Parkinson's Disease
The purpose of this study is to allow evaluation of long-term clinical effect and safety outcome of treatment with AP-CD/LD, as well as to allow patients to benefit from extended treatment duration with AP-CD/LD after they have successfully completed the Phase 3 core study IN 11 004 ('core study', a phase III, multicenter, randomized, double-blind, double-dummy, active-controlled Phase 3 study to assess the safety and efficacy of AP CD/LD versus IR CD/LD in fluctuating PD patients).
Dopamine Agonist
Accordion Pillâ„¢ Carbidopa/Levodopa for Parkinson's Disease
The purpose of this study is to determine whether the gastric retentive Accordion Pillâ„¢ Carbidopa/Levodopa (AP-CD/LD) is more effective than the commercially available immediate release Carbidopa/Levodopa in reducing motor fluctuations such as "off time" in advanced Parkinson's Disease patients.
Dopamine Agonist
Tavapadon for Parkinson's Disease
This trial is testing a medication called tavapadon to see if it can help people with Parkinson's Disease. The study will check how well the medication works, how safe it is, and how the body processes it. Tavapadon aims to balance brain chemicals that control movement, potentially reducing Parkinson's symptoms.
Trials With No Placebo
Vitamin Supplementation
PD vitamin supplementation +2 More for Parkinson's Disease
This experiment seeks to determine whether individuals with PD will benefit from vitamin B6 (pyridoxine hydrochloride), B12 (cyanocobalamin), and Folic Acid supplementation, whether they will benefit from a 6-week circuit training program, or whether they will benefit from a combination of the two interventions. The outcome variables will include: plasma homocysteine, GSH:GSSG ratio, cognitive function, balance, strength, functional activities, kinematic gait analysis, and a quality of life questionnaire.
Behavioral Intervention
Cognitive Behavioral Therapy for Parkinson's Disease
The purpose of the study is to examine the effects of a form of talk therapy called cognitive behavior therapy (CBT) in the treatment of major depression in individuals with Parkinson's disease (PD).
Radiation Therapy
Far Infrared Radiation for Parkinson's Disease
Parkinson's disease (PD) is a degenerative disorder of the central nervous system that often impairs the sufferer's motor skills and speech. This study will investigate the use of far infrared radiation to manage, control and treat PD.
Radioactive Drug
[123I]β-CIT for Parkinson's Disease
This trial is testing a new strategy to identify people at risk for Parkinson's disease before they show any symptoms. The strategy involves combining two biomarkers of parkinsonism, olfaction and brain imaging, with a radioactively labeled drug. First-degree relatives of PD patients will be recruited to participate in this study.
Behavioural Intervention
Skill-Based Exercise +1 More for Parkinson's Disease
The aim of this application is to compare and elucidate the effects of skill-based versus aerobic exercise versus control on mild cognitive impairment (MCI) of the executive function (EF) subtype in Parkinson's disease (PD); we hypothesize that skill-based exercise will result in the greatest improvement in EF and lead to modification of underlying neural substrates.
Monoamine Oxidase Inhibitor
Selegiline +1 More for Erectile Dysfunction
This trial is testing if adding selegiline to tadalafil can better treat erectile dysfunction in men with Parkinson's disease. These men haven't fully responded to tadalafil alone. Selegiline helps Parkinson's medication work better, and tadalafil improves blood flow to help with erections. Tadalafil has been proven to improve erectile function and is effective in treating erectile dysfunction associated with various conditions such as hypertension and diabetes.
View More Related Trials
Frequently Asked Questions
Introduction to parkinson
What are the top hospitals conducting parkinson research?
While clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) may still be in their early stages, several top hospitals are leading the way in advancing our understanding and treatment of this complex condition. In Toronto, the Toronto Western Hospital is currently conducting six active Parkinson's trials, showcasing its commitment to finding innovative solutions for patients. Moving south to Chicago, Rush University Medical Center has five ongoing trials focused solely on Parkinson's disease. This renowned institution is at the forefront of research and has made significant strides in improving the lives of those affected by this neurodegenerative disorder.
On the West Coast, Stanford University also prioritizes Parkinson's research with four active clinical trials. The expertise and dedication of its medical professionals contribute to groundbreaking advancements that offer hope to individuals living with Parkinson's. Meanwhile, even away from major cities like Chicago or Toronto, specialized centers like the Parkinson's Disease and Movement Disorders Center of Boca Raton are making a difference too. They're actively involved in three ongoing clinical trials dedicated exclusively to exploring new treatments for patients.
Lastly, Northwestern University in Chicago deserves recognition for its contributions as well; it is currently running three active clinical studies focused on treating and managing symptoms associated with Parkinson’s disease while earnestly working towards breakthroughs that could revolutionize how we approach this neurological condition.
These hospitals are not only providing cutting-edge care but also offering opportunities for patients to participate in ground-breaking research studies that have enormous potential implications worldwide- an exciting prospect considering there remain no previously concluded records available within these institutions specifically targeting parkinsonism thus far! Such initiatives pave way forward creating brighter outlooks against Parkinons' fight
Which are the best cities for parkinson clinical trials?
When it comes to clinical trials for [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease), several cities are at the forefront of research and advancement. New york, New York leads the pack with 19 active trials exploring treatments such as BIIB122, ExAblate Pallidotomy, and LY3884961. Philadelphia, Pennsylvania closely follows with 17 ongoing studies focused on ABBV-951, Investigational Treatment 1, and RO7486967 Arm. Additionally, Chicago in Illinois is conducting 14 active trials investigating ABBV-951, BIIB122, and Tavapadon. Lastly Los Angeles in California and Tampa in Florida both have 13 active trials each studying various potential breakthroughs like Movement task and IkT-148009 respectively. These cities offer individuals with Parkinson's disease access to cutting-edge clinical trials that may lead to new treatment options and improved quality of life.
Which are the top treatments for parkinson being explored in clinical trials?
Clinical trials are at the forefront of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research, with several promising treatments currently being explored. One standout option is gene therapy, which aims to correct genetic abnormalities associated with the condition. Another avenue under investigation is deep brain stimulation (DBS), where electrodes are implanted in specific regions of the brain to alleviate symptoms. Additionally, researchers are looking into novel medications that target specific pathways involved in Parkinson's progression, providing hope for improved treatment options in the future.
What are the most recent clinical trials for parkinson?
Exciting advancements in [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research are underway through recent clinical trials. One promising trial is evaluating the effectiveness of Waitlist Couple Pairs Parkinson's Group, a Phase 2 study that aims to improve outcomes for patients with Parkinson's. Another Phase 2 trial focuses on IkT-148009 and its potential benefits in managing the symptoms of this neurodegenerative disorder. In addition, Terazosin therapy is being investigated in a Phase 2 trial to assess its efficacy as a treatment option. These studies offer hope for improved quality of life and better management strategies for individuals living with Parkinson's disease.
What parkinson clinical trials were recently completed?
Several recent clinical trials have made significant advancements in the field of [Parkinson's disease](https://www.withpower.com/clinical-trials/parkinson's-disease) research. Notably, a trial sponsored by AbbVie completed in September 2021 focused on evaluating the efficacy of ABBV-951, a potential treatment option for this neurodegenerative disorder. Additionally, Biogen concluded their study on BIIB054, another promising therapy for Parkinson's disease, in June 2021. These important milestones highlight the ongoing efforts to discover innovative treatments that could potentially improve the lives of individuals living with Parkinson's disease.